MTOR and hepatocellular carcinoma: Moreover a strong contribution of GSK1838705A in enhancing both sorafenib and regorafenib effects has been highlighted [18,20], suggesting a close relation between the IGF1-R and PI3K/Akt/mTOR signaling pathways and HCC biology.